Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus cetuximab in unresectable stage III/IV cutaneous squamous cell carcinoma
DRKS00017255Phase 2Completed
- Sponsor
- Alcedis
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and cetuximab in cutaneous squamous cell carcinoma (cSCC), sponsored by Alcedis. Started Aug 2019; status: completed.
02
Drugs
avelumabcetuximab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on DRKS00017255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00017255.